Mr. Cameron Groome reports

MICROBIX & ACPCC SUPPORT EFFORTS TO ELIMINATE CERVICAL CANCER IN THE INDO-PACIFIC

Microbix Biosystems Inc. and the Australian Centre for the Prevention of Cervical Cancer (ACPCC), with its Australian HPV Reference Laboratory, have signed a memorandum of understanding (MOU), under which Microbix will supply its PROCEEDxFLOQ-brand quality assessment products (QAPs) to support quality management of testing for high-risk human papillomavirus (HPV) infections, which cause most cases of cervical cancer. The MOU signing took place in Microbix's exhibition booth at the 30th annual congress of the European Research Organization on Genital Infection and Neoplasia (EUROGIN 2025) in Porto, Portugal (March 16 to March 19, 2025).

The ACPCC is part of an established consortium, delivering a program called the Elimination Partnership in the Indo-Pacific for Cervical Cancer (EPICC), with support from the Australian government and philanthropic partners. The consortium delivering EPICC and its affiliated programs aims to improve the prevention, diagnosis and treatment of cervical cancer in the Indo-Pacific -- working toward the elimination of this largely preventable disease that continues to be a major health crisis in the region.

EPICC is a humanitarian and market-shaping program -- the underlying model having already been proven in countries such as Malaysia, Papua New Guinea, Vanuatu and Tuvalu. Together with affiliate programs, this phase is extending the EPICC model to add Timor-Leste, Solomon Islands, Kiribati, the Republic of the Marshall Islands, Samoa, Tonga, Fiji and Nauru -- for a total of 12 Indo-Pacific nations.

Associate professor David Hawkes, director of medical microbiology at ACPCC, stated that: "Cervical cancer is preventable by vaccination and HPV screening but remains a leading cause of death for women in the Indo-Pacific. EPICC aims to reduce the human toll of cervical cancer across the region. A key element to achieve this is making well-controlled molecular HPV tests readily available. Microbix HPV-directed PROCEEDxFLOQ and REDxFLOQ QAPs provide excellent QMS support for such testing by fully emulating patient specimens while being both highly stable and non-infectious."

Phil Casselli, senior vice-president of sales and business development at Microbix also commented: "Microbix is proud to be supporting ACPCC, the EPICC consortium and their affiliated programs by providing the world's best products for helping ensure the quality of tests for high-risk HPV. With both clinical self-collection and quality controls using Copan FLOQSwabs, ACPCC and EPICC are proving that everyone can and should receive access to accurate and timely tests to assess their risk of HPV-driven cancer. We are delighted to provide PROCEEDxFLOQ QAPs for high-risk HPV to this humanitarian program and further demonstrate the value of Microbix products in helping to ensure test quality around the world."

About Microbix Biosystems Inc.

Microbix Biosystems creates proprietary biological products for human health, with over 120 skilled employees and sales now targeting $2-million or more per month. It makes and exports a wide range of critical ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs) that support clinical lab proficiency testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows. Its antigens drive the antibody tests of approximately 100 diagnostics makers while QAPs are sold to clinical lab accreditation organizations, diagnostics companies and clinical labs. Microbix QAPs are now available in over 30 countries, supported by a network of international distributors. Microbix is ISO 9001 and ISO 13485 accredited, U.S. Food and Drug Administration registered, Australian Therapeutic Goods Administration registered, and Health Canada establishment licensed, and it provides IVDR-compliant (In Vitro Diagnostic Regulation) CE-marked (Conformite Europeene) products.

Microbix also applies its biological expertise and infrastructure to develop other proprietary products and technologies, most notably Kinlytic urokinase, a biologic thrombolytic drug used to treat blood clots, and reagents or media to support molecular diagnostic testing (for example, its DxTM for patient-sample collection). Microbix is traded on the Toronto Stock Exchange and OTCQX and headquartered in Mississauga, Ont., Canada.

We seek Safe Harbor.